CLINICAL / SCIENTIFIC PRESENTATION AND PUBLICATION HIGHLIGHTS
The information contained in each post on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma Participated in a Clinical Trial, “Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19” Published by Frontiers in Immunology
Clinical Trial Article Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19 https://www.frontiersin.org/articles/10.3389/fimmu.2022.899617/full Frontiers in Immunology Published: 01 June 2022
Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., June 2, 2022 – Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create...
21st Annual Needham Virtual Healthcare Conference – Presentation
American Association for Cancer Research (AACR) Annual Meeting 2022 – Presentation
Anti-FolRα ADC STRO-002 Induces Immunogenic Cell Death (ICD) to Enhance Anti-Tumor Activity
Sutro Biopharma Presents Nonclinical Data for Antibody-Drug Conjugate STRO-002 at the AACR Annual Meeting 2022
SOUTH SAN FRANCISCO, Calif., April 8, 2022 – Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create...
Sutro Biopharma to Present at the 21st Annual Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 5, 2022– Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create...
Sutro Biopharma Presented on Advances in Novel Immunostimulatory Antibody-Drug Conjugate Modality at the 12th Annual World ADC
SOUTH SAN FRANCISCO, Calif., March 30, 2022– Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create...
12th Annual World ADC London 2022 – Presentations
World ADC 2022 presentation titled, “A New Molecular Class to target Tumor Immunity by both disrupting the tumor and enabling the immune system” presented by Trevor Hallam, Ph.D., President of Scientific and Chief Scientific Officer.World ADC 2022 presentation...
Cowen 42nd Annual Healthcare Conference – Presentation
Sutro Biopharma to Participate in the Cowen 42nd Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., March 3, 2022– Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create...